A detailed history of Deutsche Bank Ag\ transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 333,519 shares of IBRX stock, worth $877,154. This represents 0.0% of its overall portfolio holdings.

Number of Shares
333,519
Previous 179,141 86.18%
Holding current value
$877,154
Previous $1.13 Million 9.28%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.32 - $6.7 $512,534 - $1.03 Million
154,378 Added 86.18%
333,519 $1.24 Million
Q2 2024

Aug 14, 2024

BUY
$4.82 - $9.15 $572,775 - $1.09 Million
118,833 Added 197.04%
179,141 $1.13 Million
Q1 2024

May 15, 2024

SELL
$3.23 - $6.17 $288,816 - $551,702
-89,417 Reduced 59.72%
60,308 $323,000
Q4 2023

Feb 14, 2024

BUY
$1.25 - $5.21 $119,985 - $500,097
95,988 Added 178.63%
149,725 $751,000
Q2 2023

Aug 14, 2023

SELL
$1.53 - $6.41 $3,843 - $16,101
-2,512 Reduced 4.47%
53,737 $149,000
Q1 2023

May 15, 2023

BUY
$1.35 - $4.78 $20,079 - $71,097
14,874 Added 35.95%
56,249 $102,000
Q4 2022

Feb 13, 2023

SELL
$4.35 - $6.77 $62,209 - $96,817
-14,301 Reduced 25.69%
41,375 $209,000
Q3 2022

Nov 14, 2022

BUY
$3.65 - $6.43 $50,366 - $88,727
13,799 Added 32.95%
55,676 $277,000
Q2 2022

Aug 11, 2022

BUY
$2.68 - $6.14 $8,943 - $20,489
3,337 Added 8.66%
41,877 $156,000
Q1 2022

May 13, 2022

SELL
$5.05 - $7.53 $21,563 - $32,153
-4,270 Reduced 9.97%
38,540 $216,000
Q4 2021

Feb 11, 2022

SELL
$5.67 - $10.18 $6,435 - $11,554
-1,135 Reduced 2.58%
42,810 $260,000
Q3 2021

Nov 04, 2021

SELL
$9.17 - $14.24 $3,915 - $6,080
-427 Reduced 0.96%
43,945 $428,000
Q2 2021

Aug 11, 2021

BUY
$13.41 - $22.4 $287,161 - $479,673
21,414 Added 93.27%
44,372 $634,000
Q1 2021

May 13, 2021

BUY
$12.83 - $42.25 $294,551 - $969,975
22,958 New
22,958 $545,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.05B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.